GRC has received consulting fees from Biodelivery Sciences International, Biogen, Click Therapeutics, Genzyme, Genentech, GW Pharmaceuticals, Immunic, Klein-Buendel, MedDay, MedImmune, Neurogenesis, Novartis, Osmotica, Perception Neurosciences, Recursion/Cerexis, Rekover, Roche, and TG Therapeutics; payment for medical writing from Ashfield MedComms; served on data safety monitoring boards for Alexion, AstraZeneca, Avexis, Biolinerx, Brainstorm Cell Therapeutics, Bristol Myers Squibb/Celgene, CSL Behring, Galmed, GreenValley Pharma, Mapi, Merck, Merck/Pfizer, Opko Biologics, OncoImmune, Neurim, Novartis, Ophazyme, Protalix, Sanofi, Reata, Teva Pharmaceuticals, VielaBio/Horizon, Vivius, and the US National Institutes of Health; and is the President of Pythagoras. All other authors declare no competing interests.